Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy.
MedComm (2020)
; 5(7): e607, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38911066
ABSTRACT
In a recent Nature elegant study, Wang et al. identified CD300ld, a novel functionally highly conserved tumor immunosuppressive receptor, highly expressed specifically on polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), as well as a key receptor in the regulation of recruitment and immunosuppressive function of PMN-MDSCs. Targeting CD300ld could remodel the tumor immune microenvironment, resulting in a broad-spectrum anti-tumor effect.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
MedComm (2020)
Year:
2024
Document type:
Article